Fukuda Keiichi
Department of Regenerative Medicine and Advanced Cardiac Therapeutics, Keio University School of Medicine, Tokyo, Japan.
Circ J. 2005 Dec;69(12):1431-46. doi: 10.1253/circj.69.1431.
Embryonic stem cells and bone marrow mesenchymal stem cells can be induced to differentiate into cardiomyocytes. Techniques to purify and transplant regenerated cardiomyocytes have been developed, and transplanted regenerated cardiomyocytes are capable of residing in the heart of recipients for long periods. Advances in tissue engineering technology have enabled the production of cardiomyocyte cell sheets for transplantation treatment of heart failure, without the need for a donor, and this has now reached the preclinical stage. The treatment of heart failure using cytokines to mobilize stem cells has also been explored.
胚胎干细胞和骨髓间充质干细胞可被诱导分化为心肌细胞。已开发出纯化和移植再生心肌细胞的技术，移植的再生心肌细胞能够长期驻留在受体心脏中。组织工程技术的进步使得无需供体即可生产用于心力衰竭移植治疗的心肌细胞片，目前这已进入临床前阶段。利用细胞因子动员干细胞治疗心力衰竭也已得到探索。
